Antimania Drugs Market Witnesses Rapid Growth with the Emergence of Covid-19 and Resultant Surge in Neurological Diseases
Bipolar disorder, also known as manic-depressive illness, affects millions of people in the U.S. According to National Comorbidity Survey Replication past year prevalence of bipolar disorder among adults was similar for males (2.9%) and females (2.8%). An estimated 4.4% of U.S. adults experience bipolar disorder at some time in their lives. Such scenario is expected to aid in growth of the antimania drugs market. Emergence of Covid-19 has increased the cases of neurological diseases around the world. According to a study published in September 2020, in JAMA Network Open, COVID-19 has tripled the rate of depression in US adults in all demographic groups—especially in those with financial worries. Thus, emergence of Covid-19 is also expected to aid in growth of the antimania drugs market . Bipolar disorder is divided into two main subtypes, namely, Bipolar I disorder (BP-I) and Bipolar II disorder (BP-II). Endoxifen is a potential new treatment option for acute ma...